【摘要】：目的對(duì)比普瑞巴林治療帶狀皰疹后神經(jīng)痛65例療效進(jìn)行觀察。方法隨機(jī)選擇從2016年10月至2017年10月來(lái)我院進(jìn)行治療的65例帶狀皰疹后神經(jīng)痛患者,65例患者自愿參加本研究活動(dòng)。將65例患者分為兩組,一組為觀察組,另一組為對(duì)照組,觀察組患者30例,對(duì)照組患者35例。給觀察組患者服用普瑞巴林75-150 mg,每天服用兩次治療帶狀皰疹后神經(jīng)痛;給對(duì)照組患者進(jìn)行其他有關(guān)藥物的服用,每日2-4次口服治療帶狀皰疹后神經(jīng)痛。采用視覺(jué)模擬評(píng)分(VAS)對(duì)兩組患者治療前后疼痛程度的對(duì)比,觀察周期為2個(gè)月。結(jié)果經(jīng)過(guò)為期兩個(gè)月的治療,兩組患者經(jīng)過(guò)不同方案的治療,帶狀皰疹后神經(jīng)痛顯有成效,但是觀察組的成效高于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論普瑞巴林治療帶狀皰疹后神經(jīng)痛出現(xiàn)了非常好的臨床效果,提高了患者的睡眠質(zhì)量,改善了心理疾病,為以后我國(guó)醫(yī)學(xué)界治療帶狀皰疹后神經(jīng)痛的研究提供了科學(xué)的數(shù)據(jù)[1]。
[Abstract]:Objective to compare the efficacy of pripramine in the treatment of 65 cases of postherpetic neuropain. Methods 65 patients with postherpetic neuropain who came to our hospital from October 2016 to October 2017 were randomly selected and 65 patients volunteered to participate in the study. Sixty-five patients were divided into two groups. One group was the observation group and the other was the control group. There were 30 patients in the observation group and 35 patients in the control group. The patients in the observation group were treated with Prelabin 75 鈮，

本文編號(hào)：2511045